Table 1.
IgA GMTs Stratified According to Exposure Status
| GMT (95% CI) (U/mL) | ||||
|---|---|---|---|---|
| Treatment Arm | Antibiotic Exposureb | Na | Strain WC3 | Strain 89-12 |
| Group 1 (RV5-RV5-RV5) | Yes | 25 | 256.9 (116.6–566.4) | 45.1 (22.5–90.4) |
| No | 181 | 299.6 (232.8–385.5) | 63.5 (50.9–79.2) | |
| Group 2 (RV5-RV1-RV1) | Yes | 20 | 214.0 (114.2–401.0) | 84.0 (49.2–143.2) |
| No | 187 | 216.0 (165.2–282.5) | 119.8 (96.4–148.8) | |
| Group 3 (RV5-RV5-RV1) | Yes | 22 | 211.7 (90.2–496.8) | 77.7 (36.9–163.5) |
| No | 172 | 320.6 (247.1–416.1) | 108.0 (85.1–137.1) | |
| Group 4 (RV1-RV1) | Yes | 15 | 62.8 (30.7–128.7) | 195.1 (83.2–457.7) |
| No | 272 | 37.0 (30.7–44.7) | 96.6 (77.1–121.0) | |
| Group 5 (RV1-RV5-RV5) | Yes | 32 | 180.5 (105.9–307.7) | 205.6 (109.9–384.4) |
| No | 248 | 268.9 (221.8–326) | 213.4 (172.4–264.3) | |
Abbreviations: CI, confidence interval; GMT, geometric mean titer; IgA, immunoglobulin A; RV1, Rotarix; RV5, RotaTeq.
aIgA assay data were missing for 2 subjects, 1 each in the WC3 and 89-12 groups.
bAntibiotic exposure was defined as receipt of an antibiotic within 14 days before to 7 days after receipt of rotavirus vaccine. No antibiotic exposure was defined as not meeting the criteria for antibiotic exposure.